The low 13-year actuarial risk of a clinically significant PCa diagnosis in middle-aged men with a baseline PSA level less than 2.00 ng/mL (ie, 0.4% among men with PSA levels <0.49 ng/mL, 1.5% among men with PSA levels of 0.50-0.99 ng/mL, and 5.4% among men with PSA levels of 1.00-1.99 ng/mL) suggests that men younger than 60 years with PSA levels of 1.00 to 1.99 ng/mL can undergo less intensive screening than men with higher baseline PSA levels. The gene discussed is KLK3; the disease is posterior cortical atrophy.